D3 lymph node dissection and DI formation are independent risk factors for EPSBO in AR.

Aim: To retrospectively examine efficacy and safety of oral combination of trifluridine and tipiracil hydrochloride as the second-line therapeutic agent for unresectable colorectal cancer. Patient and Methods: Treatment outcomes of 17 patients who had received TAS-102 at our Institution from January 2015 to January 2017 were analyzed. The indications for second-line TAS-102 treatment were intolerance to other multi-drug combination (four patients) or patient refusal of the standard second-line therapy (13 patients). Results: Among 17 patients who received TAS-102 as second-line therapy, partial response was observed in two (12%) and stable disease in two (12%). Outcomes of TAS-102 given as second-line therapy were: median overall survival of 5 months, response rate of 12% and disease control of 24%. Overall, no adverse events other than neutropenia were noted. Conclusion: Our findings suggest a beneficial role of TAS-102 in second-line therapy for unresectable colorectal carcinoma. Patients and MethodsWith approval of the Institutional Review Board (protocol 27-283[8168]), 17 patients who received TAS-102 as second-line therapy between January 2015 and January 2017 at The Jikei University School of Medicine Daisan Hospital were enrolled. According to RECIST 1.1 criteria (4), response rate, disease control rate and adverse effects were retrospectively examined. All patients had been diagnosed with unresectable metastatic colorectal cancer, and comparative parameters consisted of: sex, age, performance status (PS), primary tumor site, resected/not resected primary tumor, treatment stage, number of TAS-102 doses, organs of metastasis and number of metastases. TAS-102 was given orally at 35 mg/m2 twice a day for 28 days (one course): 2-Week cycles of 5 days of treatment and 2 days of rest, followed by 14 days of rest. All data analyses were performed using Microsoft Excel software. ResultsSeventeen patients received TAS-102 during the study period. The median age of patients was 65 years (range=37-83 years) and all had PS of 1 or 2; the majority of patients were men. The colon was the most frequent primary site and in more than half of the patients, the primary lesion had been resected. Previous chemotherapies included: One regimen in 1643

No abstract

No abstract

A 38-year-old male with ulcerative colitis (UC) since 28 years of age visited our institution in July 2008 complaining of right lower abdominal pain. Physical and radiographic examinations indicated acute appendicitis. Because he did not wish to undergo surgery, conservative treatment was given. Four months later, he suffered from right abdominal and back pain. Abdominal CT and MRI scans revealed a solid lobulated tumor, 7 × 5 cm in diameter, in the ileocecal region with right hydronephroureter. Colonoscopic examination demonstrated findings compatible with mild ulcerative colitis and extrinsic compression of the cecum. The orifice of the appendix was not identified. Endoscopic ultrasonography revealed an isoand hypo-echoic extramural tumor with irregularity of the muscularis propria in the cecum. The diagnosis of appendiceal carcinoma invading the cecum and right ureter was established, and he underwent right hemicolectomy. Histopathological examination revealed adenosquamous carcinoma of the appendix (pT4b, pN2 (5/29), cM0, fStage Ⅲb). To our knowledge, this is the first reported case of adenosquamous carcinoma of the appendix in association with ulcerative colitis.